vs

Side-by-side financial comparison of Freshworks Inc. (FRSH) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Freshworks Inc. is the larger business by last-quarter revenue ($228.6M vs $151.7M, roughly 1.5× Tarsus Pharmaceuticals, Inc.). Freshworks Inc. runs the higher net margin — -2.1% vs -5.5%, a 3.4% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 16.5%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 14.6%).

Freshworks Inc. is a cloud-based software-as-a-service company, founded in 2010 in Chennai, India. The company provides cloud-based tools for customer relationship management (CRM), IT service management (ITSM), and e-commerce marketing.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

FRSH vs TARS — Head-to-Head

Bigger by revenue
FRSH
FRSH
1.5× larger
FRSH
$228.6M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+111.9% gap
TARS
128.4%
16.5%
FRSH
Higher net margin
FRSH
FRSH
3.4% more per $
FRSH
-2.1%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
14.6%
FRSH

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FRSH
FRSH
TARS
TARS
Revenue
$228.6M
$151.7M
Net Profit
$-4.8M
$-8.4M
Gross Margin
84.8%
Operating Margin
11.6%
-5.3%
Net Margin
-2.1%
-5.5%
Revenue YoY
16.5%
128.4%
Net Profit YoY
-268.9%
63.8%
EPS (diluted)
$-0.02
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRSH
FRSH
TARS
TARS
Q1 26
$228.6M
Q4 25
$222.7M
$151.7M
Q3 25
$215.1M
$118.7M
Q2 25
$204.7M
$102.7M
Q1 25
$196.3M
$78.3M
Q4 24
$194.6M
$66.4M
Q3 24
$186.6M
$48.1M
Q2 24
$174.1M
$40.8M
Net Profit
FRSH
FRSH
TARS
TARS
Q1 26
$-4.8M
Q4 25
$191.4M
$-8.4M
Q3 25
$-4.7M
$-12.6M
Q2 25
$-1.7M
$-20.3M
Q1 25
$-1.3M
$-25.1M
Q4 24
$-21.9M
$-23.1M
Q3 24
$-30.0M
$-23.4M
Q2 24
$-20.2M
$-33.3M
Gross Margin
FRSH
FRSH
TARS
TARS
Q1 26
84.8%
Q4 25
85.6%
Q3 25
84.7%
Q2 25
84.8%
Q1 25
84.8%
Q4 24
84.9%
Q3 24
84.0%
Q2 24
83.8%
Operating Margin
FRSH
FRSH
TARS
TARS
Q1 26
11.6%
Q4 25
17.8%
-5.3%
Q3 25
-3.5%
-12.2%
Q2 25
-4.2%
-21.6%
Q1 25
-5.3%
-33.5%
Q4 24
-12.2%
-36.8%
Q3 24
-20.8%
-52.3%
Q2 24
-25.1%
-81.6%
Net Margin
FRSH
FRSH
TARS
TARS
Q1 26
-2.1%
Q4 25
86.0%
-5.5%
Q3 25
-2.2%
-10.6%
Q2 25
-0.8%
-19.8%
Q1 25
-0.7%
-32.1%
Q4 24
-11.3%
-34.8%
Q3 24
-16.1%
-48.7%
Q2 24
-11.6%
-81.6%
EPS (diluted)
FRSH
FRSH
TARS
TARS
Q1 26
$-0.02
Q4 25
$0.66
$-0.17
Q3 25
$-0.02
$-0.30
Q2 25
$-0.01
$-0.48
Q1 25
$0.00
$-0.64
Q4 24
$-0.07
$-0.57
Q3 24
$-0.10
$-0.61
Q2 24
$-0.07
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRSH
FRSH
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$548.2M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.0B
$343.4M
Total Assets
$1.6B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRSH
FRSH
TARS
TARS
Q1 26
$548.2M
Q4 25
$781.4M
$417.3M
Q3 25
$813.2M
$401.8M
Q2 25
$926.2M
$381.1M
Q1 25
$995.3M
$407.9M
Q4 24
$1.1B
$291.4M
Q3 24
$1.1B
$317.0M
Q2 24
$1.0B
$323.6M
Total Debt
FRSH
FRSH
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
FRSH
FRSH
TARS
TARS
Q1 26
$1.0B
Q4 25
$1.0B
$343.4M
Q3 25
$851.5M
$335.1M
Q2 25
$984.6M
$332.6M
Q1 25
$1.1B
$342.5M
Q4 24
$1.1B
$224.5M
Q3 24
$1.1B
$237.5M
Q2 24
$1.1B
$252.2M
Total Assets
FRSH
FRSH
TARS
TARS
Q1 26
$1.6B
Q4 25
$1.6B
$562.2M
Q3 25
$1.4B
$534.6M
Q2 25
$1.5B
$495.0M
Q1 25
$1.5B
$500.8M
Q4 24
$1.6B
$377.0M
Q3 24
$1.6B
$376.3M
Q2 24
$1.5B
$376.8M
Debt / Equity
FRSH
FRSH
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRSH
FRSH
TARS
TARS
Operating Cash FlowLast quarter
$62.4M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRSH
FRSH
TARS
TARS
Q1 26
$62.4M
Q4 25
$62.3M
$19.3M
Q3 25
$63.5M
$18.3M
Q2 25
$58.6M
$-29.4M
Q1 25
$58.0M
$-20.7M
Q4 24
$41.4M
$-22.2M
Q3 24
$42.3M
$-8.7M
Q2 24
$36.3M
$-14.4M
Free Cash Flow
FRSH
FRSH
TARS
TARS
Q1 26
Q4 25
$60.1M
$13.0M
Q3 25
$61.7M
$16.3M
Q2 25
$58.2M
$-30.4M
Q1 25
$56.7M
$-21.2M
Q4 24
$36.3M
$-22.3M
Q3 24
$41.3M
$-8.9M
Q2 24
$34.0M
$-15.4M
FCF Margin
FRSH
FRSH
TARS
TARS
Q1 26
Q4 25
27.0%
8.6%
Q3 25
28.7%
13.8%
Q2 25
28.4%
-29.6%
Q1 25
28.9%
-27.1%
Q4 24
18.7%
-33.5%
Q3 24
22.1%
-18.6%
Q2 24
19.5%
-37.8%
Capex Intensity
FRSH
FRSH
TARS
TARS
Q1 26
Q4 25
1.0%
4.2%
Q3 25
0.8%
1.6%
Q2 25
0.2%
1.0%
Q1 25
0.7%
0.8%
Q4 24
2.6%
0.1%
Q3 24
0.6%
0.6%
Q2 24
1.3%
2.5%
Cash Conversion
FRSH
FRSH
TARS
TARS
Q1 26
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons